ClinicalTrials.gg
CompletedNCT01059630Updated Jan 13, 2020Results posted

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

A Phase 3 interventional study of Obinutuzumab and Bendamustine in Non-Hodgkin's Lymphoma, sponsored by Genentech, Inc.. Completed at 121 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-13.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
413
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, none of them phase 3. obinutuzumab · Lymphoma, Non-Hodgkin.

Enrollment
3rd of 15
413 · median 41
Started
2010
the only one that year
Phase 3
2 of 15
none open now
Registered
2nd of 15
by date
Lead sponsor
1 of 15
Genentech, Inc.

Among the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin, this one is the 3rd largest by enrollment, is the only one that started in 2010, is one of 2 in phase 3, and was the 2nd registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

3 of the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About obinutuzumab

obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This open-label, multicenter, randomized Phase III study will investigate the efficacy, safety, pharmacokinetics and pharmacoeconomics of obinutuzumab (RO5072759, GA101) combined with bendamustine followed by continued obinutuzumab treatment (maintenance monotherapy) compared with bendamustine alone treatment in participants with rituximab-refractory indolent Non-Hodgkin's lymphoma (iNHL). The end of study was defined to when safety follow-up for all patients had been completed (2 years' safety follow-up from last dose).

03

Conditions studied

  • Non-Hodgkin's Lymphoma

Keywords

  • follicular
  • follicular lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of documented, B-lymphocyte antigen cluster of differentiation 20 plus (CD20+), iNHL
  • to any previous regimen containing rituximab (defined by participants who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen)
  • Previously treated with a maximum of four unique chemotherapy containing treatment regimens
  • All participants must have at least one bi-dimensionally (greater than [>]1.5 centimeters (cm) in its largest dimension by computed tomography [CT] scan)

Exclusion criteria

Exclusion Criteria:

  • Prior use of any monoclonal antibody (other than anti-CD20) within 3 months prior to the start of Cycle 1, prior treatment with obinutuzumab was not allowed
  • Chemotherapy or other therapy within 28 days prior to the start of Cycle 1
  • Prior treatment with bendamustine (within 2 years of the start of Cycle 1)
  • Prior stem cell transplant
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
  • History of sensitivity to mannitol
  • Central nervous system lymphoma or prior diffuse large B-cell lymphoma (DLBCL), histological evidence of transformation to high grade or diffuse large B-cell lymphoma
  • History of other that could affect compliance with the protocol or interpretation of results
  • Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization within 4 weeks
  • Participants with a history of confirmed progressive multifocal leukoencephalopathy (PML)
  • Vaccination with a a minimum of 28 days prior to randomization
  • Recent major surgery (within 4 weeks), other than for diagnosis
  • Presence of positive test results for surface antigen (HBsAg); antibody to hepatitis B core antigen [anti-HBc]) with detectable viral load (positive hepatitis B virus [HBV] deoxyribo-nucleic acid [DNA]) or
  • Participants with chronic hepatitis B or seropositive occult (HBV) infection
  • Participants with seronegative occult HBV infection or past HBV infection (defined as anti-HBc positive and HBV DNA negative) could be eligible if they were willing to be followed according to the protocol for HBV DNA testing
  • Participants positive for Hepatitis C virus (HCV) antibody were eligible only if polymerase chain reaction(PCR) was negative for HCV Ribonucleic acid (RNA)
  • Known history of (HIV) seropositive status
  • Positive test results for human T-lymphotropic virus type I (HTLV 1) virus in endemic countries
  • Women who are pregnant or lactating
  • Fertile men or women of unless 1) surgically sterile or 2) using an adequate measure of such as oral contraceptives, intrauterine device, or barrier method of contraception in conjunction with spermicidal jelly
  • Ongoing use >30 milligrams per day (mg/day) prednisone or equivalent
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
413 participants (actual)

Study arms

  • Active comparator
    Bendamustine Alone

    Participants will receive bendamustine 120 milligrams per meter square (mg/m\^2) Intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.

    Drug: Bendamustine

  • Experimental
    Obinutuzumab + Bendamustine

    Induction phase: Participants will receive bendamustine 90 mg/m\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants will also receive obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with complete response (CR), partial response (PR) or stable response (SD) then will receive obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurs first).

    Drug: Obinutuzumab · Drug: Bendamustine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Progressive Disease (PD) as Assessed by Independent Review Committee (IRC) or Death

    PD was assessed by an IRC according to the modified response criteria for indolent Non-Hodgkin's Lymphoma (iNHL) (Modified Cheson et al, 2007). PD was defined as appearance of any new lesion more than 1.5 centimeters (cm) in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50 percent (%) increase from nadir in the sum of product diameter (SPD) of any previously involved nodes, or in a single involved node, or the size of other lesions (example: splenic or hepatic nodules). To be considered PD, a lymph node with a diameter of the short axis of less than (\<) 1.0 cm must increase by greater than or equal to (≥) 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node greater than (\>) 1 cm in its short axis.

    Time frame: Baseline until PD or death, whichever occurred first (assessed at baseline, 14 days prior to Cycle [Cy] 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1, then every 3 months up to 2 years and every 6 months for next 2 years [up to 4.5 years overall])

  2. Progression-Free Survival (PFS) as Assessed by IRC

    PFS was defined as the time from randomization to the first occurrence of PD or death as assessed by an IRC according to the modified response criteria for iNHL (Modified Cheson et al, 2007). PD was defined as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be PD, a lymph node with a diameter of the short axis of \<1.0 cm must increase by ≥ 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node \>1 cm in its short axis. PFS was estimated using Kaplan-Meier method and 95% confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.

    Time frame: Baseline until PD or death, whichever occurred first (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1, then every 3 months up to 2 years and every 6 months for next 2 years [up to 4.5 years overall])

Secondary outcomes

  1. Number of Participants With PD or Death as Assessed by Investigator

    PD was assessed by an investigator according to the modified response criteria for iNHL (Modified Cheson et al, 2007). PD was defined as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be considered PD, a lymph node with a diameter of the short axis of \<1.0 cm must increase by ≥ 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node \>1 cm in its short axis.

    Time frame: Baseline until PD or death, whichever occurred first (up to 8.5 years overall))

  2. PFS as Assessed by Investigator

    PFS was defined as the time from randomization to the first occurrence of PD as assessed by an investigator according to the modified response criteria for iNHL (Modified Cheson et al, 2007), or death from any cause on study. PD was defined as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be considered PD, a lymph node with a diameter of the short axis of \<1.0 cm must increase by ≥ 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node \>1 cm in its short axis. PFS was estimated using Kaplan-Meier method and 95% CI for median was computed using the method of Brookmeyer and Crowley.

    Time frame: Baseline until PD or death, whichever occurred first (up to 8.5 years overall)

  3. Percentage of Participants With Objective Response as Assessed by IRC

    Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. IRC review was performed up clinical cutoff date of to 1 May 2015.

    Time frame: Baseline until PD or death, whichever occurred first (up to approximately 5 years)

  4. Percentage of Participants With Objective Response as Assessed by Investigator

    Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present.

    Time frame: Baseline until PD or death, whichever occurred first (up to approximately 8.5 years)

  5. Percentage of Participants With Best Overall Response (BOR) as Assessed by IRC

    BOR observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease \& disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by baseline scan \& no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic \& hepatic nodules, involvement of other organs is usually assessable \& no measurable disease should be present, SD: Failing to attain criteria needed for a CR/PR, but not fulfilling those for PD, PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions (e.g., splenic or hepatic nodules). IRC review was performed up clinical cutoff date of to 1 May 2015.

    Time frame: Baseline until PD or death, whichever occurred first (up to approximately 5 years)

  6. Percentage of Participants With Best Overall Response (BOR) as Assessed by Investigator

    BOR: best response for a participant, observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by baseline scan and no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present, SD: Failing to attain the criteria needed for a CR or PR, but not fulfilling those for PD, PD: appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in single involved node, or the size of other lesions (e.g., splenic or hepatic nodules).

    Time frame: Baseline until PD or death, whichever occurred first (up to approximately 8.5 years)

  7. Percentage of Participants With BOR at the End of Induction Treatment as Assessed by IRC

    BOR observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease \& disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan \& no new sites; no increase in size of other nodes, liver or spleen; with exception of splenic \& hepatic nodules, involvement of other organs is usually assessable \& no measurable disease should be present, SD: Failing to attain criteria needed for a CR/PR, but not fulfilling those for PD, PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or size of other lesions (e.g., splenic/hepatic nodules). IRC review was performed up clinical cutoff date of to 1 May 2015.

    Time frame: Baseline until end of induction treatment (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1)

  8. Percentage of Participants With BOR at the End of Induction Treatment as Assessed by Investigator

    BOR: best response for a participant, observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present, SD: Failing to attain criteria needed for a CR or PR, but not fulfilling those for PD, PD: appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules).

    Time frame: Baseline until end of induction treatment (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1)

  9. Percentage of Participants With Objective Response at the End of Induction Treatment as Assessed by IRC

    Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. IRC review was performed up clinical cutoff date of to 1 May 2015.

    Time frame: Baseline until end of induction treatment (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1)

  10. Percentage of Participants With Objective Response at the End of Induction Treatment as Assessed by Investigator

    Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present.

    Time frame: Baseline until end of induction treatment (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1)

  11. Duration of Response (DoR) as Assessed by IRC

    DoR: time from first objective response of CR/PR to first occurrence of PD/relapse/death from any cause. CR: Complete disappearance of all detectable evidence of disease \& disease-related symptoms if present before therapy; liver, spleen returned to normal size; if bone marrow involved by lymphoma before treatment, infiltrate must be cleared on repeat bone marrow biopsy. PR: at least 50% measurable disease regressed vs. to baseline scan and no new sites; no increase in size of other nodes/liver/spleen, exception: splenic, hepatic nodules; other organs involved is usually assessable; no measurable disease present. PD: any new lesion \>1.5 cm in any axis appear during or at end of therapy, even if other lesions are decreasing in size; at least 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions. DoR estimated using Kaplan-Meier method. IRC review performed up to clinical cutoff date 1 May 2015.

    Time frame: Baseline until PD or death, whichever occurred first (up to approximately 5 years)

  12. Duration of Response (DoR) as Assessed by Investigator

    DoR: time from first objective response of CR/PR to first occurrence of PD/relapse/death from any cause. CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy; liver, spleen returned to normal size (if enlarged at baseline); if bone marrow was involved by lymphoma prior to treatment, infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to baseline scan and no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic, hepatic nodules; involvement of other organs is usually assessable; no presence of measurable disease. PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions. DoR was estimated using Kaplan-Meier method.

    Time frame: Baseline until PD or death, whichever occurred first (up to approximately 8.5 years)

  13. Disease-Free Survival (DFS) in Participants With CR as Assessed by IRC

    DFS was defined as the time from the first occurrence of a documented CR until progression on the basis of the IRC assessments (as per modified response criteria for iNHL \[Modified Cheson et al, 2007\]) or death from any cause on study. CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in a single involved node, or size of other lesions. DFS was estimated using Kaplan-Meier method. IRC review was performed up clinical cutoff date of to 1 May 2015.

    Time frame: Baseline until PD or death, whichever occurred first (up to approximately 5 years)

  14. Disease-Free Survival (DFS) in Participants With CR as Assessed by Investigator

    DFS was defined as the time from the first occurrence of a documented CR until progression on the basis of the IRC assessments (as per modified response criteria for iNHL \[Modified Cheson et al, 2007\]) or death from any cause on study. CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in a single involved node, or size of other lesions. DFS was estimated using Kaplan-Meier method.

    Time frame: Baseline until PD or death, whichever occurred first (up to approximately 8.5 years)

  15. Event-free Survival (EFS) as Assessed by IRC

    EFS was defined as the time between the date of randomization and the date of PD/relapse based on IRC assessments (as per modified response criteria for iNHL \[Modified Cheson et al, 2007\]), death from any cause on study, or start of a new anti-lymphoma therapy. PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in a single involved node, or size of other lesions. EFS was estimated using Kaplan-Meier method. IRC review was performed up clinical cutoff date of to 1 May 2015.

    Time frame: Baseline until PD or death, whichever occurred first (up to approximately 5 years)

  16. Percentage of Participants Who Died

    Time frame: Baseline until death (up to 8.5 years overall)

  17. Overall Survival (OS)

    OS was defined as the time between the date of randomization and the date of death from any cause. OS was estimated using Kaplan-Meier method and 95% CI for median was computed using the method of Brookmeyer and Crowley.

    Time frame: Baseline until death (up to 8.5 years overall)

  18. Change From Baseline (CFB) in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)-Physical Well Being Sub-scale Score

    The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Physical Well-being sub-scale includes 7 items measured on 0-4 point scale. The total score for physical well-being sub-scale is sum of each 7 items (range: 0-28). Higher scores indicate a better participant-reported outcome (PRO)/quality of life (QoL). In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

    Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24

  19. CFB in FACT-Lym-Social/Family Well-being Sub-scale Score

    The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Social/family Well-being sub-scale includes 7 items measured on 0-4 point scale. The total score for social/family well-being sub-scale is sum of each 7 items (range: 0-28). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

    Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24

  20. CFB in FACT-Lym-Emotional Well-Being Sub-scale Score

    The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Emotional Well-being sub-scale includes 6 items measured on 0-4 point scale. The total score for emotional well-being sub-scale is sum of each 6 items (range: 0-24). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

    Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24

  21. CFB in FACT-Lym-Functional Well-Being Sub-scale Score

    The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Functional Well-being sub-scale includes 7 items measured on 0-4 point scale. The total score for functional well-being sub-scale is sum of each 7 items (range: 0-28). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

    Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24

  22. CFB in FACT-Lym-Lymphoma Sub-scale Score

    The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Lymphoma scale includes 15 items measured on 0-4 point scale. The total score for lymphoma sub-scale is sum of each 15 items (range: 0-60). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

    Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24

  23. CFB in Euro Quality of Life 5 Dimension (EuroQoL-5D/EQ-5D) - Health State Profile Utility Score During Induction Phase

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). For 'Obinutuzumab + Bendamustine' arm, participants who had their follow-up Month 2 and 4 visits before start of maintenance treatment were reported in induction phase results under "CFB at Follow-up Month 2" and "CFB at Follow-up Month 4" categories.

    Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4 and 14

  24. CFB in EuroQol 5D (EQ-5D) - Health State Profile Utility Score During Maintenance Phase

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Data for this outcome was planned to be reported only for 'Obinutuzumab + Bendamustine' arm. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). Follow-up months were during maintenance phase.

    Time frame: Baseline, Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final follow-up (up to 2 years after end of induction) (End of induction = up to Month 6)

  25. CFB in EQ-5D Visual Analogue Scale (VAS) Score During Induction Phase

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). For 'Obinutuzumab + Bendamustine' arm, participants who had their follow-up Month 2 and 4 visits before start of maintenance treatment were reported in induction phase results under "CFB at Follow-up Month 2" and "CFB at Follow-up Month 4" categories.

    Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4 and 14

  26. CFB in EQ-5D VAS Score During Maintenance Phase

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Data for this outcome was planned to be reported only for 'Obinutuzumab + Bendamustine' arm. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). Follow-up months were during maintenance phase.

    Time frame: Baseline, Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction) (end of induction = up to Month 6)

  27. CFB in Functional Assessment of Cancer Therapy - Generic (FACT-G) Score

    The FACT-G is the sum of 4 sub-scales (physical, social, emotional and functional well-being) of FACT-Lym which includes total 27 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-108. Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

    Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24

  28. CFB in FACT-Lym Trial Outcome Index (TOI)

    TOI is the sum of 3 sub-scales (physical well-being, functional well-being, and Lymphoma sub-scale) of FACT-Lym which includes total 29 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-116. Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

    Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24

  29. CFB in FACT-Lym Total Score

    FACT-Lym total score is the sum of physical well-being score (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and Lymphoma sub-scale (15 items); responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

    Time frame: Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24

  30. Time to Deterioration of FACT-Lym TOI

    The median time, in month, from date of randomization until a clinically meaningful decline from baseline in TOI or death, whichever occurred first. TOI: sum of physical well-being score,functional well-being score, and Lymphoma sub-scale of FACT-Lym; total 29 items, responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-116. Higher scores indicate a better PRO/QoL. A clinically meaningful decline in TOI score was defined as at least a 6 point decline from baseline. Time to deterioration was estimated using Kaplan-Meier method and 95% CI for median was computed using the method of Brookmeyer and Crowley. In timeframe, follow-up months represents months after end of induction (EOI) (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

    Time frame: Baseline up to approximately 8.5 years

  31. Percentage of Participants With Definitive Improvement (DI) From Baseline in FACT-Lym Instrument Scores

    FACT-Lym: 42-items in 5 subscales. Responses to each item range from 0 (Not at all) to 4 (Very much). FACT-Lym Lymphoma subscale includes 15 items (total score range = 0-60). FACT-Lym TOI is sum of 3 subscales (physical well-being, functional well-being, lymphoma subscale) and includes 29 items (total score range = 0-116). FACT-Lym total score is sum of 42 items (total score ranges from 0-168). For all above, higher scores indicate a better PRO/QoL. DI from baseline: at least 3 point increase from baseline in FACT-Lym Lymphoma subscale; at least 6 point increase from baseline in FACT Lym TOI; at least 7 point increase from baseline in FACT Lym total scores. In timeframe, follow-up months represents months after EOI (e.g. Follow-up Month 2 is 2 months after EOI; EOI = up to Month 6).

    Time frame: Baseline, Cycle 5 Day 1 (C5D1) (Cycle length = 28 days), Follow-up Months 6 (FUM6), 12 (FUM12), 18 (FUM18), 24 (FUM24), Extension Follow Up Month 6 (Extension FUM6)

07

Results

Posted Nov 17, 2016

Participant flow

Participant flow — Overall Study
MilestoneBendamustine AloneObinutuzumab + Bendamustine
Started209204
Completed82101
Not completed127103
Withdrew: Death10084
Withdrew: Lost to follow-up41
Withdrew: Physician decision24
Withdrew: Withdrawal by subject2114

Outcome measures

PrimaryNumber of Participants With Progressive Disease (PD) as Assessed by Independent Review Committee (IRC) or Death

PD was assessed by an IRC according to the modified response criteria for indolent Non-Hodgkin's Lymphoma (iNHL) (Modified Cheson et al, 2007). PD was defined as appearance of any new lesion more than 1.5 centimeters (cm) in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50 percent (%) increase from nadir in the sum of product diameter (SPD) of any previously involved nodes, or in a single involved node, or the size of other lesions (example: splenic or hepatic nodules). To be considered PD, a lymph node with a diameter of the short axis of less than (\<) 1.0 cm must increase by greater than or equal to (≥) 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node greater than (\>) 1 cm in its short axis.

Time frame:
Baseline until PD or death, whichever occurred first (assessed at baseline, 14 days prior to Cycle [Cy] 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1, then every 3 months up to 2 years and every 6 months for next 2 years [up to 4.5 years overall])
Reported as:
Number · participants
Number of Participants With Progressive Disease (PD) as Assessed by Independent Review Committee (IRC) or Death
participantsBendamustine AloneObinutuzumab + Bendamustine
Number of Participants With Progressive Disease (PD) as Assessed by Independent Review Committee (IRC) or Death12587
PrimaryProgression-Free Survival (PFS) as Assessed by IRC

PFS was defined as the time from randomization to the first occurrence of PD or death as assessed by an IRC according to the modified response criteria for iNHL (Modified Cheson et al, 2007). PD was defined as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be PD, a lymph node with a diameter of the short axis of \<1.0 cm must increase by ≥ 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node \>1 cm in its short axis. PFS was estimated using Kaplan-Meier method and 95% confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.

Time frame:
Baseline until PD or death, whichever occurred first (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1, then every 3 months up to 2 years and every 6 months for next 2 years [up to 4.5 years overall])
Reported as:
Median · months
Progression-Free Survival (PFS) as Assessed by IRC
monthsBendamustine AloneObinutuzumab + Bendamustine
Progression-Free Survival (PFS) as Assessed by IRC14.1 (11.7 to 16.6)29.2 (20.5 to NA)
Statistical analysis
  • Bendamustine Alone vs Obinutuzumab + Bendamustine · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.53 · 95% CI 0.40 to 0.70
SecondaryNumber of Participants With PD or Death as Assessed by Investigator

PD was assessed by an investigator according to the modified response criteria for iNHL (Modified Cheson et al, 2007). PD was defined as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be considered PD, a lymph node with a diameter of the short axis of \<1.0 cm must increase by ≥ 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node \>1 cm in its short axis.

Time frame:
Baseline until PD or death, whichever occurred first (up to 8.5 years overall))
Reported as:
Number · participants
Number of Participants With PD or Death as Assessed by Investigator
participantsBendamustine AloneObinutuzumab + Bendamustine
Number of Participants With PD or Death as Assessed by Investigator152132
SecondaryPFS as Assessed by Investigator

PFS was defined as the time from randomization to the first occurrence of PD as assessed by an investigator according to the modified response criteria for iNHL (Modified Cheson et al, 2007), or death from any cause on study. PD was defined as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be considered PD, a lymph node with a diameter of the short axis of \<1.0 cm must increase by ≥ 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node \>1 cm in its short axis. PFS was estimated using Kaplan-Meier method and 95% CI for median was computed using the method of Brookmeyer and Crowley.

Time frame:
Baseline until PD or death, whichever occurred first (up to 8.5 years overall)
Reported as:
Median · months
PFS as Assessed by Investigator
monthsBendamustine AloneObinutuzumab + Bendamustine
PFS as Assessed by Investigator14.1 (12.6 to 16.2)25.8 (20.1 to 36.5)
Statistical analysis
  • Bendamustine Alone vs Obinutuzumab + Bendamustine · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.57 · 95% CI 0.45 to 0.73
SecondaryPercentage of Participants With Objective Response as Assessed by IRC

Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. IRC review was performed up clinical cutoff date of to 1 May 2015.

Time frame:
Baseline until PD or death, whichever occurred first (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response as Assessed by IRC
percentage of participantsBendamustine AloneObinutuzumab + Bendamustine
Percentage of Participants With Objective Response as Assessed by IRC77.5 (71.24 to 82.98)75.5 (69.00 to 81.23)
Statistical analysis
  • Bendamustine Alone vs Obinutuzumab + Bendamustine · Cochran-Mantel-Haenszel · p = 0.9298 · Difference in response rate: 0.98 · 95% CI 0.58 to 1.65
SecondaryPercentage of Participants With Objective Response as Assessed by Investigator

Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present.

Time frame:
Baseline until PD or death, whichever occurred first (up to approximately 8.5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response as Assessed by Investigator
percentage of participantsBendamustine AloneObinutuzumab + Bendamustine
Percentage of Participants With Objective Response as Assessed by Investigator83.3 (77.49 to 88.05)82.4 (76.42 to 87.32)
Statistical analysis
  • Bendamustine Alone vs Obinutuzumab + Bendamustine · Cochran-Mantel-Haenszel · p = 0.7857 · Difference in response rate: -0.90 · 95% CI -8.44 to 6.64
SecondaryPercentage of Participants With Best Overall Response (BOR) as Assessed by IRC

BOR observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease \& disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by baseline scan \& no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic \& hepatic nodules, involvement of other organs is usually assessable \& no measurable disease should be present, SD: Failing to attain criteria needed for a CR/PR, but not fulfilling those for PD, PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions (e.g., splenic or hepatic nodules). IRC review was performed up clinical cutoff date of to 1 May 2015.

Time frame:
Baseline until PD or death, whichever occurred first (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Response (BOR) as Assessed by IRC
percentage of participantsBendamustine AloneObinutuzumab + Bendamustine
CR17.2 (12.37 to 23.04)16.2 (11.40 to 21.96)
PR60.3 (53.31 to 66.97)59.3 (52.23 to 66.12)
SD12.0 (7.89 to 17.15)13.7 (9.32 to 19.22)
PD5.7 (3.00 to 9.81)4.9 (2.38 to 8.83)
Unable to evaluate1.0 (0.12 to 3.41)1.0 (0.12 to 3.50)
Missing3.8 (1.67 to 7.40)4.9 (2.38 to 8.83)
SecondaryPercentage of Participants With Best Overall Response (BOR) as Assessed by Investigator

BOR: best response for a participant, observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by baseline scan and no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present, SD: Failing to attain the criteria needed for a CR or PR, but not fulfilling those for PD, PD: appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in single involved node, or the size of other lesions (e.g., splenic or hepatic nodules).

Time frame:
Baseline until PD or death, whichever occurred first (up to approximately 8.5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Response (BOR) as Assessed by Investigator
percentage of participantsBendamustine AloneObinutuzumab + Bendamustine
CR21.5 (16.16 to 27.73)23.5 (17.89 to 29.96)
PR61.7 (54.76 to 68.34)58.8 (51.74 to 65.65)
SD6.7 (3.71 to 10.98)6.4 (3.44 to 10.65)
PD4.8 (2.32 to 8.62)6.4 (3.44 to 10.65)
Unable to evaluate1.4 (0.30 to 4.14)0.5 (0.01 to 2.70)
Missing3.8 (1.67 to 7.40)4.4 (2.04 to 8.21)
SecondaryPercentage of Participants With BOR at the End of Induction Treatment as Assessed by IRC

BOR observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease \& disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan \& no new sites; no increase in size of other nodes, liver or spleen; with exception of splenic \& hepatic nodules, involvement of other organs is usually assessable \& no measurable disease should be present, SD: Failing to attain criteria needed for a CR/PR, but not fulfilling those for PD, PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or size of other lesions (e.g., splenic/hepatic nodules). IRC review was performed up clinical cutoff date of to 1 May 2015.

Time frame:
Baseline until end of induction treatment (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With BOR at the End of Induction Treatment as Assessed by IRC
percentage of participantsBendamustine AloneObinutuzumab + Bendamustine
CR12.0 (7.93 to 17.23)11.8 (7.69 to 17.00)
PR52.4 (45.38 to 59.35)54.9 (47.80 to 61.86)
SD10.1 (6.36 to 15.02)11.8 (7.69 to 17.00)
PD10.6 (6.75 to 15.58)8.8 (5.31 to 13.59)
Unable to Evaluate2.9 (1.07 to 6.17)2.0 (0.54 to 4.94)
Missing12.0 (7.93 to 17.23)10.8 (6.88 to 15.87)
SecondaryPercentage of Participants With BOR at the End of Induction Treatment as Assessed by Investigator

BOR: best response for a participant, observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present, SD: Failing to attain criteria needed for a CR or PR, but not fulfilling those for PD, PD: appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules).

Time frame:
Baseline until end of induction treatment (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With BOR at the End of Induction Treatment as Assessed by Investigator
percentage of participantsBendamustine AloneObinutuzumab + Bendamustine
CR15.8 (11.12 to 21.45)17.2 (12.25 to 23.04)
PR53.1 (46.10 to 60.03)60.3 (53.23 to 67.06)
SD4.3 (1.99 to 8.02)3.9 (1.71 to 7.58)
PD12.0 (7.89 to 17.15)9.3 (5.70 to 14.16)
Unable to Evaluate2.9 (1.06 to 6.14)0.5 (0.01 to 2.70)
Missing12.0 (7.89 to 17.15)8.8 (5.31 to 13.59)
SecondaryPercentage of Participants With Objective Response at the End of Induction Treatment as Assessed by IRC

Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. IRC review was performed up clinical cutoff date of to 1 May 2015.

Time frame:
Baseline until end of induction treatment (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response at the End of Induction Treatment as Assessed by IRC
percentage of participantsBendamustine AloneObinutuzumab + Bendamustine
Percentage of Participants With Objective Response at the End of Induction Treatment as Assessed by IRC64.4 (57.51 to 70.92)66.7 (59.75 to 73.10)
Statistical analysis
  • Bendamustine Alone vs Obinutuzumab + Bendamustine · Cochran-Mantel-Haenszel · p = 0.8347 · Difference in response rate: 2.24 · 95% CI -7.20 to 11.69
SecondaryPercentage of Participants With Objective Response at the End of Induction Treatment as Assessed by Investigator

Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present.

Time frame:
Baseline until end of induction treatment (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response at the End of Induction Treatment as Assessed by Investigator
percentage of participantsBendamustine AloneObinutuzumab + Bendamustine
Percentage of Participants With Objective Response at the End of Induction Treatment as Assessed by Investigator68.9 (62.15 to 75.11)77.5 (71.09 to 82.99)
Statistical analysis
  • Bendamustine Alone vs Obinutuzumab + Bendamustine · Cochran-Mantel-Haenszel · p = 0.0466 · Difference in response rate: 8.55 · 95% CI -0.22 to 17.32
SecondaryDuration of Response (DoR) as Assessed by IRC

DoR: time from first objective response of CR/PR to first occurrence of PD/relapse/death from any cause. CR: Complete disappearance of all detectable evidence of disease \& disease-related symptoms if present before therapy; liver, spleen returned to normal size; if bone marrow involved by lymphoma before treatment, infiltrate must be cleared on repeat bone marrow biopsy. PR: at least 50% measurable disease regressed vs. to baseline scan and no new sites; no increase in size of other nodes/liver/spleen, exception: splenic, hepatic nodules; other organs involved is usually assessable; no measurable disease present. PD: any new lesion \>1.5 cm in any axis appear during or at end of therapy, even if other lesions are decreasing in size; at least 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions. DoR estimated using Kaplan-Meier method. IRC review performed up to clinical cutoff date 1 May 2015.

Time frame:
Baseline until PD or death, whichever occurred first (up to approximately 5 years)
Reported as:
Median · months
Duration of Response (DoR) as Assessed by IRC
monthsBendamustine AloneObinutuzumab + Bendamustine
Duration of Response (DoR) as Assessed by IRC12.7 (10.4 to 14.1)38.5 (25.4 to NA)
Statistical analysis
  • Bendamustine Alone vs Obinutuzumab + Bendamustine · Hazard ratio (hr): 0.43 · 95% CI 0.31 to 0.61
SecondaryDuration of Response (DoR) as Assessed by Investigator

DoR: time from first objective response of CR/PR to first occurrence of PD/relapse/death from any cause. CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy; liver, spleen returned to normal size (if enlarged at baseline); if bone marrow was involved by lymphoma prior to treatment, infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to baseline scan and no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic, hepatic nodules; involvement of other organs is usually assessable; no presence of measurable disease. PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions. DoR was estimated using Kaplan-Meier method.

Time frame:
Baseline until PD or death, whichever occurred first (up to approximately 8.5 years)
Reported as:
Median · months
Duration of Response (DoR) as Assessed by Investigator
monthsBendamustine AloneObinutuzumab + Bendamustine
Duration of Response (DoR) as Assessed by Investigator12.7 (11.1 to 15.5)32.3 (20.8 to 39.0)
Statistical analysis
  • Bendamustine Alone vs Obinutuzumab + Bendamustine · Hazard ratio (hr): 0.51 · 95% CI 0.39 to 0.67
SecondaryDisease-Free Survival (DFS) in Participants With CR as Assessed by IRC

DFS was defined as the time from the first occurrence of a documented CR until progression on the basis of the IRC assessments (as per modified response criteria for iNHL \[Modified Cheson et al, 2007\]) or death from any cause on study. CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in a single involved node, or size of other lesions. DFS was estimated using Kaplan-Meier method. IRC review was performed up clinical cutoff date of to 1 May 2015.

Time frame:
Baseline until PD or death, whichever occurred first (up to approximately 5 years)
Reported as:
Median · months
Disease-Free Survival (DFS) in Participants With CR as Assessed by IRC
monthsBendamustine AloneObinutuzumab + Bendamustine
Disease-Free Survival (DFS) in Participants With CR as Assessed by IRC13.2 (8.5 to NA)NA (NA to NA)
Statistical analysis
  • Bendamustine Alone vs Obinutuzumab + Bendamustine · Hazard ratio (hr): 0.13 · 95% CI 0.04 to 0.45
SecondaryDisease-Free Survival (DFS) in Participants With CR as Assessed by Investigator

DFS was defined as the time from the first occurrence of a documented CR until progression on the basis of the IRC assessments (as per modified response criteria for iNHL \[Modified Cheson et al, 2007\]) or death from any cause on study. CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in a single involved node, or size of other lesions. DFS was estimated using Kaplan-Meier method.

Time frame:
Baseline until PD or death, whichever occurred first (up to approximately 8.5 years)
Reported as:
Median · months
Disease-Free Survival (DFS) in Participants With CR as Assessed by Investigator
monthsBendamustine AloneObinutuzumab + Bendamustine
Disease-Free Survival (DFS) in Participants With CR as Assessed by Investigator20.0 (8.6 to 31.0)36.0 (26.6 to 68.2)
Statistical analysis
  • Bendamustine Alone vs Obinutuzumab + Bendamustine · Hazard ratio (hr): 0.48 · 95% CI 0.29 to 0.81
SecondaryEvent-free Survival (EFS) as Assessed by IRC

EFS was defined as the time between the date of randomization and the date of PD/relapse based on IRC assessments (as per modified response criteria for iNHL \[Modified Cheson et al, 2007\]), death from any cause on study, or start of a new anti-lymphoma therapy. PD: appearance of any new lesion \>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in a single involved node, or size of other lesions. EFS was estimated using Kaplan-Meier method. IRC review was performed up clinical cutoff date of to 1 May 2015.

Time frame:
Baseline until PD or death, whichever occurred first (up to approximately 5 years)
Reported as:
Median · months
Event-free Survival (EFS) as Assessed by IRC
monthsBendamustine AloneObinutuzumab + Bendamustine
Event-free Survival (EFS) as Assessed by IRC13.7 (11.4 to 15.5)25.3 (13.9 to 35.0)
Statistical analysis
  • Bendamustine Alone vs Obinutuzumab + Bendamustine · Log Rank · p = 0.0001 · Hazard ratio (hr): 0.57 · 95% CI 0.44 to 0.74
SecondaryPercentage of Participants Who Died
Time frame:
Baseline until death (up to 8.5 years overall)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died
percentage of participantsBendamustine AloneObinutuzumab + Bendamustine
Percentage of Participants Who Died49.341.2
SecondaryOverall Survival (OS)

OS was defined as the time between the date of randomization and the date of death from any cause. OS was estimated using Kaplan-Meier method and 95% CI for median was computed using the method of Brookmeyer and Crowley.

Time frame:
Baseline until death (up to 8.5 years overall)
Reported as:
Median · months
Overall Survival (OS)
monthsBendamustine AloneObinutuzumab + Bendamustine
Overall Survival (OS)65.6 (48.5 to 87.8)88.3 (71.1 to NA)
Statistical analysis
  • Bendamustine Alone vs Obinutuzumab + Bendamustine · Log Rank · p = 0.0810 · Hazard ratio (hr): 0.77 · 95% CI 0.57 to 1.03
SecondaryChange From Baseline (CFB) in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)-Physical Well Being Sub-scale Score

The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Physical Well-being sub-scale includes 7 items measured on 0-4 point scale. The total score for physical well-being sub-scale is sum of each 7 items (range: 0-28). Higher scores indicate a better participant-reported outcome (PRO)/quality of life (QoL). In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

Time frame:
Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24
Reported as:
Mean · units on a scale
Change From Baseline (CFB) in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)-Physical Well Being Sub-scale Score
units on a scaleBendamustine AloneObinutuzumab + Bendamustine
Baseline22.58 ± 5.2322.76 ± 4.61
CFB at Cycle 3 Day 1-1.56 ± 5.49-0.69 ± 4.06
CFB at Cycle 4 Day 1-6.80 ± 4.21-3.00 ± 2.83
CFB at Cycle 5 Day 1-1.82 ± 5.06-0.72 ± 4.16
CFB at End of Induction Treatment-1.00 ± 5.14-0.61 ± 4.62
CFB at Follow-up Month 20.62 ± 5.140.58 ± 4.45
CFB at Follow-up Month 40.53 ± 4.580.88 ± 4.47
CFB at Follow-up Month 60.29 ± 3.740.91 ± 3.82
CFB at Follow-up Month 8-0.01 ± 3.530.87 ± 3.96
CFB at Follow-up Month 100.06 ± 4.160.56 ± 3.81
CFB at Follow-up Month 120.26 ± 4.020.74 ± 4.24
CFB at Follow-up Month 140.03 ± 4.140.71 ± 3.94
CFB at Follow-up Month 16-0.10 ± 3.491.31 ± 3.68
CFB at Follow-up Month 18-0.22 ± 3.640.92 ± 3.99
CFB at Follow-up Month 20-0.36 ± 3.700.74 ± 3.69
CFB at Follow-up Month 22-0.25 ± 3.930.40 ± 4.47
CFB at Follow-up Month 24-0.77 ± 4.160.52 ± 4.42
CFB at Final Follow-up0.16 ± 4.170.22 ± 4.47
CFB at Extension Follow-up Month 60.36 ± 3.480.57 ± 4.71
CFB at Extension Follow-up Month 180.80 ± 2.541.19 ± 4.98
CFB at Extension Follow-up Month 241.53 ± 5.960.56 ± 5.26
SecondaryCFB in FACT-Lym-Social/Family Well-being Sub-scale Score

The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Social/family Well-being sub-scale includes 7 items measured on 0-4 point scale. The total score for social/family well-being sub-scale is sum of each 7 items (range: 0-28). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

Time frame:
Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24
Reported as:
Mean · units on a scale
CFB in FACT-Lym-Social/Family Well-being Sub-scale Score
units on a scaleBendamustine AloneObinutuzumab + Bendamustine
Baseline22.04 ± 5.6522.14 ± 5.51
CFB at Cycle 3 Day 1-0.21 ± 3.59-0.10 ± 3.87
CFB at Cycle 4 Day 1-1.00 ± 3.673.11 ± 2.83
CFB at Cycle 5 Day 1-0.34 ± 4.32-0.34 ± 4.33
CFB at End of Induction Treatment-0.65 ± 5.21-0.88 ± 3.60
CFB at Follow-up Month 2-0.02 ± 4.83-0.57 ± 5.37
CFB at Follow-up Month 40.27 ± 4.65-0.26 ± 5.02
CFB at Follow-up Month 60.05 ± 4.46-0.08 ± 4.64
CFB at Follow-up Month 8-0.68 ± 3.67-0.37 ± 4.99
CFB at Follow-up Month 100.56 ± 5.000.13 ± 5.14
CFB at Follow-up Month 120.06 ± 5.89-0.47 ± 5.64
CFB at Follow-up Month 140.56 ± 3.28-0.03 ± 4.16
CFB at Follow-up Month 160.36 ± 6.79-0.15 ± 5.28
CFB at Follow-up Month 180.44 ± 6.230.04 ± 5.35
CFB at Follow-up Month 20-0.66 ± 4.280.00 ± 5.75
CFB at Follow-up Month 220.29 ± 7.12-0.50 ± 5.02
CFB at Follow-up Month 24-1.29 ± 3.91-0.41 ± 5.24
CFB at Final Follow-up-0.19 ± 4.91-0.52 ± 5.56
CFB at Extension Follow-up Month 6-0.35 ± 2.49-0.16 ± 4.92
CFB at Extension Follow-up Month 18-0.15 ± 2.920.71 ± 5.26
CFB at Extension Follow-up Month 24-0.41 ± 3.180.44 ± 5.02
SecondaryCFB in FACT-Lym-Emotional Well-Being Sub-scale Score

The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Emotional Well-being sub-scale includes 6 items measured on 0-4 point scale. The total score for emotional well-being sub-scale is sum of each 6 items (range: 0-24). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

Time frame:
Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24
Reported as:
Mean · units on a scale
CFB in FACT-Lym-Emotional Well-Being Sub-scale Score
units on a scaleBendamustine AloneObinutuzumab + Bendamustine
Baseline17.38 ± 4.4517.81 ± 4.33
CFB at Cycle 3 Day 10.61 ± 3.040.78 ± 3.14
CFB at Cycle 4 Day 1-0.60 ± 3.853.40 ± 4.42
CFB at Cycle 5 Day 10.37 ± 3.080.50 ± 3.52
CFB at End of Induction Treatment0.53 ± 3.570.59 ± 4.03
CFB at Follow-up Month 20.66 ± 3.890.67 ± 3.83
CFB at Follow-up Month 41.34 ± 3.540.95 ± 3.51
CFB at Follow-up Month 60.89 ± 3.570.96 ± 3.44
CFB at Follow-up Month 80.26 ± 3.350.97 ± 3.34
CFB at Follow-up Month 100.69 ± 3.311.32 ± 3.23
CFB at Follow-up Month 12-0.07 ± 3.880.95 ± 3.29
CFB at Follow-up Month 140.46 ± 3.221.07 ± 3.82
CFB at Follow-up Month 160.13 ± 3.871.04 ± 3.69
CFB at Follow-up Month 180.42 ± 3.361.00 ± 3.38
CFB at Follow-up Month 20-0.43 ± 2.900.94 ± 4.28
CFB at Follow-up Month 220.18 ± 2.810.97 ± 3.79
CFB at Follow-up Month 240.06 ± 3.201.12 ± 3.78
CFB at Final Follow-up0.38 ± 3.770.34 ± 4.37
CFB at Extension Follow-up Month 6-0.44 ± 3.260.39 ± 3.99
CFB at Extension Follow-up Month 18-0.08 ± 3.800.75 ± 3.85
CFB at Extension Follow-up Month 241.04 ± 4.160.97 ± 4.36
SecondaryCFB in FACT-Lym-Functional Well-Being Sub-scale Score

The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Functional Well-being sub-scale includes 7 items measured on 0-4 point scale. The total score for functional well-being sub-scale is sum of each 7 items (range: 0-28). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

Time frame:
Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24
Reported as:
Mean · units on a scale
CFB in FACT-Lym-Functional Well-Being Sub-scale Score
units on a scaleBendamustine AloneObinutuzumab + Bendamustine
Baseline17.98 ± 6.3117.90 ± 6.08
CFB at Cycle 3 Day 1-0.54 ± 4.650.38 ± 4.66
CFB at Cycle 4 Day 1-0.80 ± 2.281.78 ± 4.91
CFB at Cycle 5 Day 1-0.71 ± 5.040.67 ± 5.35
CFB at End of Induction Treatment-0.50 ± 5.500.00 ± 5.25
CFB at Follow-up Month 20.31 ± 5.270.65 ± 5.38
CFB at Follow-up Month 40.24 ± 5.111.31 ± 5.86
CFB at Follow-up Month 60.95 ± 4.581.26 ± 5.08
CFB at Follow-up Month 8-0.27 ± 4.380.92 ± 5.45
CFB at Follow-up Month 101.09 ± 4.251.00 ± 5.52
CFB at Follow-up Month 120.18 ± 5.591.78 ± 6.04
CFB at Follow-up Month 141.16 ± 4.271.22 ± 4.84
CFB at Follow-up Month 160.91 ± 3.971.69 ± 5.95
CFB at Follow-up Month 180.21 ± 4.121.84 ± 5.77
CFB at Follow-up Month 20-0.27 ± 4.901.43 ± 6.14
CFB at Follow-up Month 22-0.32 ± 5.700.82 ± 5.00
CFB at Follow-up Month 24-0.96 ± 4.360.98 ± 5.87
CFB at Final Follow-up-0.08 ± 4.940.50 ± 6.19
CFB at Extension Follow-up Month 61.01 ± 3.510.85 ± 6.65
CFB at Extension Follow-up Month 180.96 ± 4.511.90 ± 6.50
CFB at Extension Follow-up Month 242.22 ± 3.342.62 ± 6.95
SecondaryCFB in FACT-Lym-Lymphoma Sub-scale Score

The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Lymphoma scale includes 15 items measured on 0-4 point scale. The total score for lymphoma sub-scale is sum of each 15 items (range: 0-60). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

Time frame:
Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24
Reported as:
Mean · units on a scale
CFB in FACT-Lym-Lymphoma Sub-scale Score
units on a scaleBendamustine AloneObinutuzumab + Bendamustine
Baseline44.79 ± 9.6645.61 ± 9.17
CFB at Cycle 3 Day 10.98 ± 6.971.24 ± 5.71
CFB at Cycle 4 Day 1-2.80 ± 5.769.50 ± 3.54
CFB at Cycle 5 Day 10.75 ± 6.791.41 ± 6.21
CFB at End of Induction Treatment1.64 ± 7.100.74 ± 7.89
CFB at Follow-up Month 23.44 ± 6.782.45 ± 6.22
CFB at Follow-up Month 42.77 ± 6.712.39 ± 6.54
CFB at Follow-up Month 62.33 ± 6.443.00 ± 7.05
CFB at Follow-up Month 81.79 ± 6.012.52 ± 6.69
CFB at Follow-up Month 101.90 ± 6.782.28 ± 6.82
CFB at Follow-up Month 122.12 ± 6.472.89 ± 6.42
CFB at Follow-up Month 140.48 ± 6.642.58 ± 6.37
CFB at Follow-up Month 160.44 ± 7.793.27 ± 6.14
CFB at Follow-up Month 181.18 ± 6.092.91 ± 6.79
CFB at Follow-up Month 200.57 ± 7.432.83 ± 6.41
CFB at Follow-up Month 221.89 ± 8.622.55 ± 6.58
CFB at Follow-up Month 240.66 ± 7.592.73 ± 6.48
CFB at Final Follow-up1.62 ± 7.171.33 ± 7.38
CFB at Extension Follow-up Month 60.92 ± 5.062.98 ± 7.22
CFB at Extension Follow-up Month 181.80 ± 8.302.35 ± 5.72
CFB at Extension Follow-up Month 244.89 ± 6.672.23 ± 6.85
SecondaryCFB in Euro Quality of Life 5 Dimension (EuroQoL-5D/EQ-5D) - Health State Profile Utility Score During Induction Phase

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). For 'Obinutuzumab + Bendamustine' arm, participants who had their follow-up Month 2 and 4 visits before start of maintenance treatment were reported in induction phase results under "CFB at Follow-up Month 2" and "CFB at Follow-up Month 4" categories.

Time frame:
Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4 and 14
Reported as:
Mean · units on a scale
CFB in Euro Quality of Life 5 Dimension (EuroQoL-5D/EQ-5D) - Health State Profile Utility Score During Induction Phase
units on a scaleBendamustine AloneObinutuzumab + Bendamustine
Baseline0.77 ± 0.220.79 ± 0.20
CFB at Cycle 3 Day 10.03 ± 0.210.00 ± 0.19
CFB at Cycle 4 Day 1-0.10 ± 0.23-0.07 ± 0.41
CFB at Cycle 5 Day 10.01 ± 0.210.02 ± 0.20
CFB at End of Induction Treatment0.01 ± 0.220.01 ± 0.20
CFB at Follow-up Month 20.06 ± 0.240.04 ± 0.18
CFB at Follow-up Month 4—-0.12 ± 0.00
CFB at Follow-up Month 140.12 ± NA—
SecondaryCFB in EuroQol 5D (EQ-5D) - Health State Profile Utility Score During Maintenance Phase

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Data for this outcome was planned to be reported only for 'Obinutuzumab + Bendamustine' arm. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). Follow-up months were during maintenance phase.

Time frame:
Baseline, Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final follow-up (up to 2 years after end of induction) (End of induction = up to Month 6)
Reported as:
Mean · units on a scale
CFB in EuroQol 5D (EQ-5D) - Health State Profile Utility Score During Maintenance Phase
units on a scaleBendamustine AloneObinutuzumab + Bendamustine
CFB at Follow-up Month 2—-0.15 ± 0.22
CFB at Follow-up Month 40.15 ± NA0.03 ± 0.22
CFB at Follow-up Month 60.15 ± NA0.04 ± 0.19
CFB at Follow-up Month 80.15 ± NA0.04 ± 0.21
CFB at Follow-up Month 100.15 ± NA0.03 ± 0.20
CFB at Follow-up Month 12—0.06 ± 0.18
CFB at Follow-up Month 14—0.06 ± 0.19
CFB at Follow-up Month 16—0.05 ± 0.19
CFB at Follow-up Month 18—0.05 ± 0.18
CFB at Follow-up Month 20—0.05 ± 0.20
CFB at Follow-up Month 22—0.05 ± 0.24
CFB at Follow-up Month 24—0.03 ± 0.22
CFB at Final Follow-up—0.03 ± 0.25
SecondaryCFB in EQ-5D Visual Analogue Scale (VAS) Score During Induction Phase

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). For 'Obinutuzumab + Bendamustine' arm, participants who had their follow-up Month 2 and 4 visits before start of maintenance treatment were reported in induction phase results under "CFB at Follow-up Month 2" and "CFB at Follow-up Month 4" categories.

Time frame:
Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4 and 14
Reported as:
Mean · units on a scale
CFB in EQ-5D Visual Analogue Scale (VAS) Score During Induction Phase
units on a scaleBendamustine AloneObinutuzumab + Bendamustine
Baseline69.48 ± 20.7168.03 ± 21.69
CFB at Cycle 3 Day 10.91 ± 19.383.32 ± 15.99
CFB at Cycle 4 Day 1-14.00 ± 33.29-4.33 ± 42.15
CFB at Cycle 5 Day 10.35 ± 20.795.17 ± 17.35
CFB at End of Induction Treatment5.71 ± 61.885.82 ± 22.20
CFB at Follow-up Month 25.19 ± 19.126.85 ± 18.95
CFB at Follow-up Month 4—0.00 ± 14.14
CFB at Follow-up Month 1410.00 ± NA—
SecondaryCFB in EQ-5D VAS Score During Maintenance Phase

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Data for this outcome was planned to be reported only for 'Obinutuzumab + Bendamustine' arm. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). Follow-up months were during maintenance phase.

Time frame:
Baseline, Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction) (end of induction = up to Month 6)
Reported as:
Mean · units on a scale
CFB in EQ-5D VAS Score During Maintenance Phase
units on a scaleBendamustine AloneObinutuzumab + Bendamustine
CFB at Follow-up Month 2—-40.00 ± NA
CFB at Follow-up Month 45.00 ± NA5.59 ± 19.61
CFB at Follow-up Month 65.00 ± NA6.04 ± 19.00
CFB at Follow-up Month 85.00 ± NA4.79 ± 17.18
CFB at Follow-up Month 10-15.00 ± NA4.62 ± 16.28
CFB at Follow-up Month 12—5.73 ± 16.04
CFB at Follow-up Month 14—5.45 ± 17.36
CFB at Follow-up Month 16—6.66 ± 17.44
CFB at Follow-up Month 18—6.13 ± 19.44
CFB at Follow-up Month 20—7.56 ± 15.43
CFB at Follow-up Month 22—6.97 ± 15.55
CFB at Follow-up Month 24—8.28 ± 16.23
CFB at Final Follow-up—4.47 ± 14.91
SecondaryCFB in Functional Assessment of Cancer Therapy - Generic (FACT-G) Score

The FACT-G is the sum of 4 sub-scales (physical, social, emotional and functional well-being) of FACT-Lym which includes total 27 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-108. Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

Time frame:
Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24
Reported as:
Mean · Units on a scale
CFB in Functional Assessment of Cancer Therapy - Generic (FACT-G) Score
Units on a scaleBendamustine AloneObinutuzumab + Bendamustine
Baseline79.86 ± 16.2580.78 ± 16.27
CFB at Cycle 3 Day 1-1.87 ± 12.280.11 ± 10.30
CFB at Cycle 4 Day 1-9.37 ± 9.890.52 ± 4.98
CFB at Cycle 5 Day 1-2.44 ± 12.010.06 ± 11.13
CFB at End of Induction Treatment-1.84 ± 13.83-0.92 ± 11.77
CFB at Follow-up Month 21.53 ± 13.421.22 ± 12.01
CFB at Follow-up Month 42.55 ± 11.473.06 ± 13.00
CFB at Follow-up Month 62.54 ± 10.683.24 ± 11.40
CFB at Follow-up Month 8-0.53 ± 10.152.49 ± 11.45
CFB at Follow-up Month 102.29 ± 11.393.46 ± 11.83
CFB at Follow-up Month 120.68 ± 13.162.82 ± 14.29
CFB at Follow-up Month 142.48 ± 9.422.94 ± 11.97
CFB at Follow-up Month 161.54 ± 10.614.09 ± 12.87
CFB at Follow-up Month 181.16 ± 11.574.06 ± 13.36
CFB at Follow-up Month 20-1.21 ± 12.253.05 ± 14.29
CFB at Follow-up Month 220.64 ± 14.271.80 ± 12.43
CFB at Follow-up Month 24-2.39 ± 9.322.28 ± 13.83
CFB at Final Follow-up0.50 ± 11.250.78 ± 14.94
CFB at Extension Follow Up Month 60.48 ± 8.711.74 ± 14.23
CFB at Extension Follow Up Month 182.29 ± 8.404.56 ± 15.02
CFB at Extension Follow Up Month 244.48 ± 11.104.47 ± 15.22
SecondaryCFB in FACT-Lym Trial Outcome Index (TOI)

TOI is the sum of 3 sub-scales (physical well-being, functional well-being, and Lymphoma sub-scale) of FACT-Lym which includes total 29 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-116. Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

Time frame:
Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24
Reported as:
Mean · Units on a scale
CFB in FACT-Lym Trial Outcome Index (TOI)
Units on a scaleBendamustine AloneObinutuzumab + Bendamustine
Baseline84.66 ± 19.3684.76 ± 18.97
CFB at Cycle 3 Day 1-1.94 ± 17.961.81 ± 13.88
CFB at Cycle 4 Day 1-10.40 ± 10.3826.44 ± 19.51
CFB at Cycle 5 Day 1-1.38 ± 15.382.37 ± 14.15
CFB at End of Induction Treatment-0.52 ± 17.230.40 ± 16.45
CFB at Follow-up Month 23.75 ± 15.364.60 ± 14.85
CFB at Follow-up Month 43.81 ± 13.395.18 ± 17.06
CFB at Follow-up Month 63.26 ± 12.196.07 ± 13.72
CFB at Follow-up Month 81.36 ± 12.395.36 ± 14.21
CFB at Follow-up Month 103.52 ± 13.164.94 ± 15.96
CFB at Follow-up Month 122.05 ± 15.146.13 ± 15.72
CFB at Follow-up Month 142.25 ± 11.925.13 ± 14.30
CFB at Follow-up Month 160.75 ± 14.156.78 ± 15.11
CFB at Follow-up Month 181.36 ± 11.307.26 ± 14.62
CFB at Follow-up Month 20-0.64 ± 15.216.36 ± 14.99
CFB at Follow-up Month 222.26 ± 14.545.30 ± 17.88
CFB at Follow-up Month 24-0.14 ± 13.445.30 ± 17.88
CFB at Final Follow-up0.84 ± 14.803.84 ± 16.22
CFB at Extension Follow Up Month 62.30 ± 10.775.53 ± 18.44
CFB at Extension Follow Up Month 184.02 ± 14.017.31 ± 15.69
CFB at Extension Follow Up Month 2410.04 ± 13.357.07 ± 17.59
SecondaryCFB in FACT-Lym Total Score

FACT-Lym total score is the sum of physical well-being score (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and Lymphoma sub-scale (15 items); responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-168. Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

Time frame:
Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24
Reported as:
Mean · Units on a scale
CFB in FACT-Lym Total Score
Units on a scaleBendamustine AloneObinutuzumab + Bendamustine
Baseline124.56 ± 24.17126.22 ± 23.98
CFB at Cycle 3 Day 1-0.74 ± 17.911.33 ± 13.89
CFB at Cycle 4 Day 1-12.16 ± 14.8022.53 ± 16.23
CFB at Cycle 5 Day 1-1.68 ± 16.611.71 ± 15.23
CFB at End of Induction Treatment0.02 ± 18.550.35 ± 18.29
CFB at Follow-up Month 25.10 ± 17.733.54 ± 15.45
CFB at Follow-up Month 45.40 ± 16.295.50 ± 17.76
CFB at Follow-up Month 65.03 ± 15.016.57 ± 15.96
CFB at Follow-up Month 81.48 ± 14.275.18 ± 15.61
CFB at Follow-up Month 104.58 ± 16.395.70 ± 16.89
CFB at Follow-up Month 122.97 ± 17.845.88 ± 18.93
CFB at Follow-up Month 143.18 ± 13.855.92 ± 17.06
CFB at Follow-up Month 162.25 ± 14.987.59 ± 16.97
CFB at Follow-up Month 182.16 ± 15.386.99 ± 18.27
CFB at Follow-up Month 20-0.89 ± 16.345.66 ± 18.90
CFB at Follow-up Month 222.15 ± 19.034.59 ± 17.98
CFB at Follow-up Month 24-2.13 ± 15.745.28 ± 18.75
CFB at Final follow-up2.15 ± 16.602.55 ± 20.11
CFB at Extension Follow Up Month 61.22 ± 11.675.14 ± 20.30
CFB at Extension Follow Up Month 184.92 ± 14.736.88 ± 19.24
CFB at Extension Follow Up Month 249.69 ± 15.886.13 ± 20.32
SecondaryTime to Deterioration of FACT-Lym TOI

The median time, in month, from date of randomization until a clinically meaningful decline from baseline in TOI or death, whichever occurred first. TOI: sum of physical well-being score,functional well-being score, and Lymphoma sub-scale of FACT-Lym; total 29 items, responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-116. Higher scores indicate a better PRO/QoL. A clinically meaningful decline in TOI score was defined as at least a 6 point decline from baseline. Time to deterioration was estimated using Kaplan-Meier method and 95% CI for median was computed using the method of Brookmeyer and Crowley. In timeframe, follow-up months represents months after end of induction (EOI) (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).

Time frame:
Baseline up to approximately 8.5 years
Reported as:
Median · Months
Time to Deterioration of FACT-Lym TOI
MonthsBendamustine AloneObinutuzumab + Bendamustine
Time to Deterioration of FACT-Lym TOI5.6 (3.9 to 7.0)8.0 (5.9 to 14.7)
SecondaryPercentage of Participants With Definitive Improvement (DI) From Baseline in FACT-Lym Instrument Scores

FACT-Lym: 42-items in 5 subscales. Responses to each item range from 0 (Not at all) to 4 (Very much). FACT-Lym Lymphoma subscale includes 15 items (total score range = 0-60). FACT-Lym TOI is sum of 3 subscales (physical well-being, functional well-being, lymphoma subscale) and includes 29 items (total score range = 0-116). FACT-Lym total score is sum of 42 items (total score ranges from 0-168). For all above, higher scores indicate a better PRO/QoL. DI from baseline: at least 3 point increase from baseline in FACT-Lym Lymphoma subscale; at least 6 point increase from baseline in FACT Lym TOI; at least 7 point increase from baseline in FACT Lym total scores. In timeframe, follow-up months represents months after EOI (e.g. Follow-up Month 2 is 2 months after EOI; EOI = up to Month 6).

Time frame:
Baseline, Cycle 5 Day 1 (C5D1) (Cycle length = 28 days), Follow-up Months 6 (FUM6), 12 (FUM12), 18 (FUM18), 24 (FUM24), Extension Follow Up Month 6 (Extension FUM6)
Reported as:
Number · Percentage of participants
Percentage of Participants With Definitive Improvement (DI) From Baseline in FACT-Lym Instrument Scores
Percentage of participantsBendamustine AloneObinutuzumab + Bendamustine
C5D1 (>=3 pt increase)30.341.7
FUM6 (>=3 pt increase)37.947.1
FUM12 (>=3 pt increase)36.746.5
FUM18 (>=3 pt increase)35.653.0
FUM24 (>=3 pt increase)35.350
Ext FUM6 (>=3 pt increase)36.057.8
C5D1 (>=6 pt increase)23.134.4
FUM6 (>=6 pt increase)29.543.7
FUM12 (>=6 pt increase)26.247.0
FUM18 (>=6 pt increase)28.951.8
FUM24 (>=6 pt increase)26.548.0
Ext FUM6 (>=6 pt increase)4456.9
C5D1 (>=7 pt increase)24.428.0
FUM6 (>=7 pt increase)34.140.3
FUM12 (>=7 pt increase)31.145.0
FUM18 (>=7 pt increase)31.143.4
FUM24 (>=7 pt increase)20.642.7
Ext FUM6 (>=7 pt increase)3247.7

Adverse events

Collected over Baseline up to 8.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bendamustine Alone—76/203 (37.4%)194/203 (95.6%)
Obinutuzumab + Bendamustine—91/204 (44.6%)200/204 (98%)
Most frequent serious events
Showing 10 of 143
Most frequent serious events
EventBendamustine AloneObinutuzumab + Bendamustine
PNEUMONIAInfections and infestations12/2037/204
FEBRILE NEUTROPENIABlood and lymphatic system disorders6/20311/204
SEPSISInfections and infestations7/2036/204
INFUSION RELATED REACTIONInjury, poisoning and procedural complications3/2037/204
NEUTROPENIABlood and lymphatic system disorders1/2036/204
PYREXIAGeneral disorders3/2036/204
THROMBOCYTOPENIABlood and lymphatic system disorders0/2035/204
ANAEMIABlood and lymphatic system disorders3/2033/204
DIARRHOEAGastrointestinal disorders3/2030/204
BRONCHITISInfections and infestations3/2031/204
Most frequent other events
Showing 10 of 48
Most frequent other events
EventBendamustine AloneObinutuzumab + Bendamustine
INFUSION RELATED REACTIONInjury, poisoning and procedural complications115/203125/204
NAUSEAGastrointestinal disorders123/203107/204
FATIGUEGeneral disorders67/20381/204
NEUTROPENIABlood and lymphatic system disorders59/20374/204
COUGHRespiratory, thoracic and mediastinal disorders40/20364/204
DIARRHOEAGastrointestinal disorders61/20357/204
VOMITINGGastrointestinal disorders54/20344/204
PYREXIAGeneral disorders36/20354/204
THROMBOCYTOPENIABlood and lymphatic system disorders50/20326/204
CONSTIPATIONGastrointestinal disorders40/20342/204

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Bendamustine AloneObinutuzumab + BendamustineTotal
Mean61.9 ± 11.562.0 ± 11.361.9 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Bendamustine AloneObinutuzumab + BendamustineTotal
Female8788175
Male122116238
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bendamustine AloneObinutuzumab + BendamustineTotal
Hispanic or Latino5611
Not Hispanic or Latino174183357
Not Stated301545
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bendamustine AloneObinutuzumab + BendamustineTotal
American Indian or Alaska Native213
Asian369
Black or African American358
Multiple101
Unknown191231
White181180361
08

Study locations

121 sites
  • Southern Cancer Center, PC
    Mobile, Alabama 36608, United States
  • Dr. Donald W. Hill, MD, FACP
    Casa Grande, Arizona 85122, United States
  • Highlands Oncology Group
    Rogers, Arkansas 72758, United States
  • Kaiser Permanente - Bellflower
    Bellflower, California 90706, United States
  • Bay Area Cancer Research Group, LLC
    Pleasant Hill, California 94523, United States
  • Sharp Memorial Hospital
    San Diego, California 92123, United States
  • Georgetown University Medical Center Lombardi Cancer Center
    Washington, District of Columbia 20007, United States
  • Washington DC VA Med Center; Hematology
    Washington, District of Columbia 20422, United States
  • University of Florida
    Gainesville, Florida 32607, United States
  • University of Florida; Division of Hematology/Oncology
    Gainesville, Florida 33610-0277, United States
  • Md Anderson Cancer Center Orlando
    Orlando, Florida 32806, United States
  • Rush Cancer Institute
    Chicago, Illinois 60612, United States
  • Quincy Medical Group
    Quincy, Illinois 62301, United States
  • Simmons Cancer Institute
    Springfield, Illinois 62794-9677, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Univ Louisville School of Med
    Louisville, Kentucky 40202, United States
  • New England Cancer Specialists
    Scarborough, Maine 04074, United States
  • Meritus Center for Clinical Research
    Hagerstown, Maryland 21740, United States
  • Capitol Comprehensive CA Care
    Jefferson City, Missouri 65101, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Hematology Oncology Assoc SJ
    Mount Holly, New Jersey 08060, United States
  • San Juan Oncology
    Farmington, New Mexico 87401, United States
  • The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc.
    Columbus, Ohio 43219, United States
  • OHSU Knight Cancer Institute
    Portland, Oregon 97210, United States
  • Pacific Oncology, PC
    Portland, Oregon 97210, United States
  • OHSU Ctr for Health & Healing
    Portland, Oregon 97239, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Western Pennsylvania Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • Sanford Health System
    Sioux Falls, South Dakota 57105, United States
  • South Texas Inst of Cancer
    Corpus Christi, Texas 78405, United States
  • University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Univ of Wisconsin Hosp & Clin
    Madison, Wisconsin 53792, United States
  • Lkh-Univ. Klinikum Graz
    Graz, 8036, Austria
  • Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
    Salzburg, 5020, Austria
  • Medizinische Universität Wien
    Wien, 1090, Austria
  • ZNA Stuivenberg
    Antwerpen, 2060, Belgium
  • AZ Groeninge
    Kortrijk, 8500, Belgium
  • CHU Ambroise Paré
    Mons, 7000, Belgium
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • British Columbia Cancer Agency
    Kelowna, British Columbia V1Y 5L3, Canada
  • British Columbia Cancer Agency
    Vancouver, British Columbia V5Z 1H6, Canada
  • Manitoba Cancer Care
    Winnipeg, Manitoba R3E 0V9, Canada
  • Moncton Hospital
    Moncton, New Brunswick E1C 6Z8, Canada
  • Toronto East General Hospital; Main Pharmacy G Wing Basement
    East York, Ontario M4C 3E7, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M4X 1K9, Canada
  • CHUM-Hosp Notre Dame
    Montreal, Quebec H2X 3E4, Canada
  • McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology
    Montreal, Quebec H3T 1E2, Canada
  • CHA Hopital de I enfant-Jesus
    Quebec City, Quebec G1J 1Z4, Canada
  • Allan Blair Cancer Centre
    Regina, Saskatchewan S4T 7T1, Canada
  • Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika
    Brno, 625 00, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • I Interni klinika; Vseobecna fakultni nemocnice
    Prague 2, 128 08, Czechia
  • Institut Bergonie; Hematologie Oncologie
    Bordeaux, 33076, France
  • Polyclinique Bordeaux Nord
    Bordeaux, 33300, France
  • Hopital Henri Mondor
    Creteil, 94010, France
  • CH Dijon
    Dijon, 21079, France
  • Centre d'oncologie-radiotherap
    LeMans, 72015, France
  • Hopital Claude Huriez
    Lille, 59037, France
  • Centre Leon Berard
    Lyon, 69008, France
  • Hopital Bon Secour
    Metz, 57038, France
  • CHU Hopital Saint Eloi
    Montpellier, 34295, France
  • Hopital Hotel Dieu Et Hme; Clinique Dermatologique
    Nantes, 44093, France
  • Hopital Necker
    Paris, 75015, France
  • Hopital Saint Louis; Dermatologie 1
    Paris, 75475, France
  • CHU Bordeaux
    Pessac, 33604, France
  • Centre Hospitalier Lyon Sud; Hematolgie
    Pierre Benite, 69495, France
  • Chu De Poitiers; Chu La Miletrie
    Poitiers, 86021, France
  • CHU de Reims
    Reims, 51100, France
  • Hopital Pontchaillou
    Rennes, 35033, France
  • Centre Henri Becquerel
    Rouen, 76038, France
  • Clinique Ste Anne
    Strasbourg, 67000, France
  • CHRU de; Maladies, Vasculaires
    Vandoeuvre, 54511, France
  • St. Johannes Hospital Duisburg
    Duisburg, 47166, Germany
  • Klinikum Frankfurt Höchst
    Frankfurt am Main, 65929, Germany
  • Asklepios Klinik St. Georg
    Hamburg, 20099, Germany
  • Universitaetsklinikum Leipzig
    Leipzig, 04103, Germany
  • Klinikum der Universitat Munchen, Campus Grobhadern;; Medizinische Klinik und Poliklinik III
    München, 81377, Germany
  • Schwarzwald-Baar Klinikum GmbH
    Villingen-Schwenningen, 78052, Germany
  • Azienda Ospedaliera Universitaria di Modena
    Modena, Emilia-Romagna 41100, Italy
  • Azienda Ospedaliera Univ, Ematologica
    Udine, Friuli-Venezia Giulia 33100, Italy
  • Azienda Ospedaliera Univ
    Roma, Lazio 00133, Italy
  • Universita La Sapienza
    Roma, Lazio 00161, Italy
  • Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
    Milano, Lombardia 20133, Italy
  • Irccs Policlinico San Matteo; Divisione Di Ematologia
    Pavia, Lombardia 27100, Italy
  • Azienda Ospedale San Giovanni
    Torino, Piemonte 10126, Italy
  • Ospedale Mauriziano Umberto I
    Torino, Piemonte 10128, Italy
  • Ospedale Vito Fazzi
    Lecce, Puglia 73100, Italy
  • Azienda Ospedaliero Univ
    Catania, Sicilia 95124, Italy
  • Azienda Ospedaliera Univ
    Firenze, Toscana 50141, Italy
  • VU MEDISCH CENTRUM; Dept. of Medical Oncology
    Amsterdam, 1081 HV, Netherlands
  • Haga Ziekenhuis
    Den Haag, 2504 LN, Netherlands
  • Albert Schweitzer Ziekenhuis
    Dordrecht, 3371 NM, Netherlands
  • Universitair Medisch Centrum Groningen
    Groningen, 9713 GZ, Netherlands
  • Erasmus Mc - Daniel Den Hoed Kliniek; Medical Oncology
    Rotterdam, 3015 CE, Netherlands
  • Erasmus MC
    Rotterdam, 3015 GD, Netherlands
  • Regional Oncology Hospital
    Irkutsk, 664035, Russian Federation
  • Blokhin Cancer Research Center; Combined Treatment
    Moscow, 115478, Russian Federation
  • City Clin Hosp n.a. S.P.Botkin
    Moscow, 125101, Russian Federation
  • Russian Hema Res Ctr of RAMS
    Moscow, 125167, Russian Federation

Showing the first 100 of 121 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Pott C, Sehn LH, Belada D, Gribben J, Hoster E, Kahl B, Kehden B, Nicolas-Virelizier E, Spielewoy N, Fingerle-Rowson G, Harbron C, Mundt K, Wassner-Fritsch E, Cheson BD. MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. Leukemia. 2020 Feb;34(2):522-532. doi: 10.1038/s41375-019-0559-9. Epub 2019 Aug 28. PubMed 31462735 ↗
  • Gibiansky E, Gibiansky L, Buchheit V, Frey N, Brewster M, Fingerle-Rowson G, Jamois C. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study. Br J Clin Pharmacol. 2019 Sep;85(9):1935-1945. doi: 10.1111/bcp.13974. Epub 2019 Jul 12. PubMed 31050355 ↗
  • Cheson BD, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27. PubMed 29584548 ↗
  • Sehn LH, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23. PubMed 27345636 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2010 to primary completion in Sep 2014, 53 months.

Results were first posted in Nov 2016, 2 years 1 month after primary completion. A results delay was requested in Sep 2015.

Of 41 industry-sponsored phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 84. This study's 53 months is below that.

Counting every sponsor, half of 58 studies reached it within 68 months; a quarter within 43 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2010
First posted
Feb 1, 2010
StartActual
Apr 30, 2010
Primary completionActual
Sep 30, 2014
CompletionActual
Nov 30, 2018
Results delay requested
Sep 1, 2015
Results first posted
Nov 17, 2016
Last update
Jan 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01059630
Lead sponsor
Genentech, Inc.
Collaborators
Roche Pharma AG
Responsible party
Sponsor
First posted
Feb 1, 2010
Start date
Apr 30, 2010
Primary completion
Sep 30, 2014
Completion
Nov 30, 2018
Results posted
Nov 17, 2016
Last update
Jan 13, 2020

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obinutuzumab

Start the discussion